Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease metabolic syndrome x
Comorbidity C0006142|breast cancer
Sentences 16
PubMedID- 25979298 Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer.
PubMedID- 21490772 Two population-based screening surveys involving norwegian women found that low hdl-cholesterol, as part of the metabolic syndrome, is associated with increased post-menopausal breast cancer risk, and hdl-cholesterol association was confined to women in the heavier subgroup with body mass index (bmi) ≥25 kg/m2 [50].
PubMedID- 25083463 metabolic syndrome in breast cancer.
PubMedID- 25233884 Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer.
PubMedID- 26030767 Results: presence of metabolic syndrome was associated with significantly increased breast cancer risk in all women (hr 1.52, 95%ci 1.14-2.02).
PubMedID- 22740197 Several studies have examined the association of the individual components of the metabolic syndrome with breast cancer.
PubMedID- 19851862 The association of metabolic syndrome with triple-negative breast cancer.
PubMedID- 24319454 This also suggests that prevalence rates of metabolic syndrome in breast cancer patients remain similar before and after cancer treatment.
PubMedID- 25653879 metabolic syndrome is associated with increased breast cancer risk: a systematic review with meta-analysis.
PubMedID- 25979299 Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer.
PubMedID- 26175188 Adherence to wcrf/aicr cancer prevention recommendations and metabolic syndrome in breast cancer patients.
PubMedID- 23227958 The authors hypothesized that the higher prevalence of abdominal obesity and metabolic syndrome among women with triple-negative breast cancer and its link to adrenergic dysregulation and also high expression of beta-adrenergic receptors in triple-negative breast cancer cell lines could make these patients particularly sensitive to beta-blocker treatment.
PubMedID- 24783905 We must point out that cardiovascular disease risk conferred by metabolic syndrome may increase with breast cancer treatment.
PubMedID- 21249376 Objective: this study was aimed to assess the prevalence of metabolic syndrome in patients with breast cancer and the independent effect of metabolic syndrome on breast cancer risk.
PubMedID- 24344007 The relationship of insulin resistance and metabolic syndrome with known breast cancer prognostic factors in postmenopausal breast cancer patients.
PubMedID- 23981814 Results from those studies reported statistically significant higher prevalence of metabolic syndrome in breast cancer patients with respect to healthy ones (35% vs. 19%) after menopause.

Page: 1